Clik here to view.
Final Patient Enrolled in Landmark Alzheimer’s Treatment Trial Targeting...
SYDNEY Actinogen Medical ASX: ACW (‘ACW’ or ‘the Company’) is pleased to announce it has enrolled the final patient into XanADu, its Phase II clinical trial of Xanamem in the treatment of patients...
View ArticleClik here to view.
日印の協業が尿道狭窄の新規治療法を生み出す
東京 （ビジネスワイヤ） — 患者の頬粘膜細胞を使用した男性尿道狭窄の新規治療法として、痛みが比較的少ない方法が患者6人のうち4人で成功したとの報告がなされました。本研究は、日本の生体材料技術の研究者とインドの泌尿器科医のDr Suryaprakash Vaddiの共同研究の成果として、日本泌尿器科学会の公式誌であるInternational Journal of...
View ArticleClik here to view.
FDA Approves the ACTPen for Genentech’s Actemra, a Single-Dose, Prefilled...
SOUTH SAN FRANCISCO, Calif. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved ACTPen™ 162 mg/0.9 mL,...
View ArticleClik here to view.
Zymeworks and BeiGene Announce License and Collaboration Agreement for...
VANCOUVER, Canada & BEIJING & CAMBRIDGE, Mass. Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, and BeiGene, Ltd. (Nasdaq:...
View ArticleClik here to view.
European Commission Approves ALUNBRIG® (brigatinib) for ALK+ Non-Small Cell...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) granted marketing authorization for ALUNBRIG (brigatinib) as a...
View ArticleClik here to view.
GI Dynamics Announces Agreement with Apollo Sugar to Study EndoBarrier in India
BOSTON & SYDNEY & HYDERABAD, India GI Dynamics Inc. (ASX: GID), a medical device company that is developing EndoBarrier for patients diagnosed with type 2 diabetes and obesity, is pleased to...
View ArticleClik here to view.
Celltrion and Teva Announce FDA Approval of TRUXIMA® (rituximab-abbs), a...
INCHEON, South Korea & JERUSALEM Celltrion, Inc. (KRX:068270) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has...
View ArticleClik here to view.
Hong Kong High Court Issues Declaratory Orders and Permanent Injunctive...
BEIJING Senior management of Sinovac Biotech Ltd. (NASDAQ: SVA) (“Sinovac” or the “Company”) and the lawful directors of Sinovac Hong Kong, Mr. Yin Weidong and Ms. Wang Nan (“Lawful Directors”),...
View ArticleClik here to view.
欧盟委员会核准ALUNBRIG® (brigatinib)用于既往接受过克唑替尼治疗的ALK+非小细胞肺癌患者，促进欧洲治疗范式
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TSE: 4502)今天宣布，欧盟委员会(EC)核准ALUNBRIG...
View ArticleClik here to view.
腰痛治療にユニバーサルドナー細胞療法製品を使用するためのSpinalCyteによるIND申請をFDAが承認
ヒューストン （ビジネスワイヤ） — テキサスに拠点を置き、ユニバーサルドナー細胞製品CybroCell™を使用した椎間板髄核再生に傾注する再生医療技術企業のSpinalCyte,...
View ArticleClik here to view.
Clik here to view.
欧州委員会がクリゾチニブによる前治療歴のあるALK陽性非小細胞肺がん患者の治療薬としてALUNBRIG®（ブリガチニブ）を承認し、欧州における治療パラダイ...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE:...
View ArticleClik here to view.
Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE:4502) today announced that data from the Phase 3 randomized, TOURMALINE-MM3 study evaluating the effect of single-agent...
View ArticleClik here to view.
LEO Pharma initiates phase 2b clinical studies of topical delgocitinib cream...
BALLERUP, Denmark LEO Pharma A/S, a global leader in medical dermatology, announces today that it has enrolled the first patients in two new phase 2b clinical studies to investigate delgocitinib, a...
View ArticleClik here to view.
Takeda Announces Execution of Loan Agreement in Connection with Proposed...
OSAKA, Japan NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH...
View ArticleClik here to view.
Schrödinger and SPARC Announce Collaboration to Accelerate Neurodegeneration...
MUMBAI & NEW YORK Schrödinger and Sun Pharma Advanced Research Company Ltd. (SPARC) (Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) today announced a research collaboration to...
View ArticleClik here to view.
Alteogen and Lynkogen Expand Agreement to Include Additional Proprietary...
DAEJEON, South Korea & EAST WINDSOR, N.J. Alteogen Inc. (196170.KQ) and Lynkogen Inc. today announced that they have expanded the scope of their exclusive option agreement. In addition to the...
View ArticleClik here to view.
TRIGR Therapeutics Expands Bispecific Immuno-Oncology Pipeline with Exclusive...
IRVINE, Calif. & SEOUL, South Korea TRIGR Therapeutics, Inc. (“TRIGR”), and ABL Bio, Inc. (“ABL”), today announced that they have entered into a collaboration and license agreement for TR009...
View ArticleClik here to view.
ティジアナ、肝細胞がんにおけるMilciclibの忍容性・抗腫瘍活性を評価するための第2a相試験で患者組み入れを完了
ニューヨーク & ロンドン （ビジネスワイヤ） — 炎症／腫瘍適応症向け革新的治療薬の創薬・開発に傾注するバイオテクノロジー企業のティジアナ・ライフ・サイエンシズ（Nasdaq: TLSA / AIM:...
View ArticleClik here to view.
ACM Global Laboratories任命Brian Wright为总裁
纽约州罗切斯特和伦敦 (美国商业资讯) — Rochester Regional Health (RRH)是一家22亿美元的综合性医疗保健交付系统，拥有超过17,000名员工，该组织宣布其全资子公司ACM Global Laboratories已聘请Brian Wright来领导ACM Global。 ACM的母公司Rochester Regional Health总裁兼首席执行官Eric...
View Article